Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance
Author:
Funder
AstraZeneca
TG Therapeutics
AbbVie Inc. | AbbVie Biotherapeutics
Tolero Pharma
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/s41408-021-00426-2.pdf
Reference15 articles.
1. Ding, W. et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br. J. Haematol. 147, 471–483 (2009).
2. Braggio, E. et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia. 26, 1698–1701 (2012).
3. Sinha, S. et al. Targeted Axl inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic/additive effects in combination with btk inhibitors. Clin. Cancer Res. 21, 2115–2126 (2015).
4. Sinha, S. et al. Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells. Leukemia 30, 1431–1436 (2016).
5. Penzes, K. et al. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Cancer Biol. Ther. 15, 1571–1582 (2014).
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications;British Journal of Cancer;2024-06-17
2. Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications;Frontiers in Oncology;2024-04-03
3. TAM family kinases as therapeutic targets at the interface of cancer and immunity;Nature Reviews Clinical Oncology;2023-09-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3